Back to Search
Start Over
miR-223-5p serves as a diagnostic biomarker for acute coronary syndrome and its predictive value for the clinical outcome after PCI.
- Source :
- BMC Cardiovascular Disorders; 8/13/2024, Vol. 24 Issue 1, p1-7, 7p
- Publication Year :
- 2024
-
Abstract
- Background: Acute coronary syndrome (ACS) is a serious cardiovascular disease that severely affects the quality of life and longevity of patients. MicroRNAs (miRNAs) play a key role in the progression of ACS with significant clinical value. The aim of this study was to examine the clinical value of miR-223-5p in ACS and on the occurrence of major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI). Methods: The plasma expression of miR-223-5p was detected by RT-qPCR. The correlation of miR-223-5p and cTnI or Gensini score was shown by the Pearson method. Risk factors for the development of ACS were analyzed by multivariate logistic regression. The efficacy of miR-223-5p in identifying patients with ACS was shown by ROC curve. The predictive value of miR-223-5p for MACE development in ACS patients within 6 months after PCI was assessed by Kaplan-Meier curve and multivariate Cox regression. Results: miR-223-5p levels were markedly elevated in ACS patients. miR-223-5p was found to be positively related to cTnI or Gensini score. miR-223-5p was a risk factor for ACS and significantly identified patients with ACS. MACE was more likely to occur after PCI in patients with high miR-223-5p levels, and miR-223-5p was an independent prognostic indicator of MACE. Conclusions: miR-223-5p had diagnostic value for ACS and predicted MACE after PCI. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14712261
- Volume :
- 24
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- BMC Cardiovascular Disorders
- Publication Type :
- Academic Journal
- Accession number :
- 179038899
- Full Text :
- https://doi.org/10.1186/s12872-024-04088-3